Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes
Authors' conclusion
Pharmacological adjunct therapies show potential for improving body composition and physical function during GLP-1 RA-induced weight loss.
Study context
- Population
- Individuals with overweight and T2D treated with GLP-1 RAs; preclinical and clinical studies of compounds with documented anabolic effects and established safety profiles
- Comparison
- Pharmacological adjunct therapies to preserve or increase lean body mass (LBM) during GLP-1 RA-induced weight loss
- Outcome
- Changes in LBM, fat mass (FM), physical function, and adverse events
Methodological detailspreclinical and clinical studies, Sources: PubMed, JAMA, Wiley, ResearchGate, The Royal Danish Library, ClinicalTrials.gov
- Preclinical and clinical studies
- Sources: PubMed, JAMA, Wiley, ResearchGate, The Royal Danish Library, ClinicalTrials.gov
Main finding
As reported in the abstract
LBM, FM and physical function
- Activin II receptor inhibition with bimagrumab: significant preservation and increases in LBM, with fat mass (FM) reduction, in preclinical and phase 2 studies in overweight and T2D
- Similar effects with myostatin and activin A inhibitors (trevogrumab, garetosmab), latent myostatin inhibitors (apitegromab, SRK-439) and SARMs (enobosarm)
- Enobosarm also improved physical function
Safety
- Adverse events generally mild and reversible; long-term data limited
Original publication
Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes. Diabetes Obes Metab. Published 3 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →